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Introduction 
Chemotherapeutic drug delivery systems are continually 
being researched. How to deliver the drug efficiently, and 
how to ensure that the medication does not affect healthy 
tissue cells, or organs have been the subject of much 
research in this area. Lipid nanoparticle for therapeutic 
cancer delivery drugs promises more efficacy1-4. PEGylated 
drug systems and Redox-triggered mitoxantrone prodrug 
micelles have been evaluated by researchers for how they 
add effectiveness in drug delivery5-8. 
 Researchers have identified that in controlling Bcl-2 which 
is an overexpressed anti-apoptotic gene in cancer growth, 
the use of lipid nanoparticles loaded G3139-GAP was more 
efficient for controlling the gene and reducing cancer 
growth9-13. LNPs showed better encapsulation efficiency. 
Bcl-2 expression was downregulated from 40 percent to 
83 percent, and this was observed in the mRNA and 
protein levels. Lipid nanoparticle delivery did not only 
inhibit tumor growth and downregulated the bcl-2 
expression, but also prolonged survival and influenced 
better prognosis14-18. In a similar format of investigation, it 
is identified that researchers have discussed the 
microRNA-21 (miR-21) which shows upregulation in some 
types of cancer. Antimi R-21 inhibits the oncomiR. LNPs 
helps in the efficient delivery of the AM-21. The role played 
by an LNP QTsome was investigated. QTsome is an amine 
and tertiary amine cationic lipids combined to create a 
unique pH responsible profile19-22. Studies showed that the 
QTsome delivered AM-21 improved the sensitivity of cells, 
and induced upregulation of miR-21. 
PEGylated liposomes of DOX is a form of modified 
Doxorubicin. The modified liposomal DOC works with 
active targeting ligands such as antibodies, proteins, and 
peptides. Many studies on Pegylated drug delivery identify 
it as a simple modification method that can be further 
enhanced based on the nature of cancer growth23-26. 
Functionality can be extended, and this warrants further 
study of pegylated liposomes. DOX which receives a bad 
reputation on account of the cytotoxicity that it induces 
can be better administered without causing adverse health 
reactions on the health care client27-31. Many studies have 
argued, the advantages of PEGylated drug delivery system 
as being more efficient, and capable when it comes to 
crossing the blood-tissue barrier to reach the tumor cells. 
PEGylated drug systems also induct more targeted drug 
delivery. The use of PEG not only creates more stable drug 
delivery, but it also can improve the drug circulation time. 
This is critical for drug efficacy. The below Figure 1 
represents the action of PEGylated liposomes in drug 
delivery.
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Figure 1: Pegylated liposomes in drug delivery-Schematic Illustration 
 
Thus, the works on pegylated liposome and targeted drug 
delivery for cancer and the use of lipid nanoparticles for 
chemotherapeutic drug delivery indicate many options 
available for treating patients32-36. The diverse systems are 
to be considered based on the type of cancer, the current 
issues of cytotoxicity adverse effects and concerns like MDR 
that the patient might exhibit. The techniques are very 
promising and are some of the existing lines of 
investigations in cancer treatments.  
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